Lyell Immunopharma (LYEL)

• Market cap: $534M
• 1 day: -1.91%
• 5 days: 6.3%
• 1 month: 3.29%
• 3 months: -24.75%
• 6 months: 89.02%
• Year to date: -13.25%
• 1 year: 88.88%
• 5 years: -92.56%
• 10 years: -92.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300